All Outputs (72)

Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C. (2014)
Journal Article
Patel, K., Remlinger, K. S., Walker, T. G., Leitner, P., Lucas, J. E., Gardner, S. D., …Guha, I. N. (2014). Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C. Clinical Gastroenterology and Hepatology, 12(12), 2113-2120.e3. https://doi.org/10.1016/j.cgh.2014.04.037

Background & Aims: Noninvasive tests cannot differentiate between adjacent stages of fibrosis, which limits assessment of disease progression and regression during therapy. We investigated whether levels of cytokines and extracellular matrix proteins... Read More about Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C..

Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection (2014)
Journal Article
Lattimore, S., Irving, W. L., Collins, S., Penman, C., & Ramsay, M. (2014). Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection. Hepatology, 59(4), 1343-1350. https://doi.org/10.1002/hep.26926

The aim of this work was to develop and validate an algorithm to monitor rates of, and response to, treatment of patients infected with hepatitis C virus (HCV) across England using routine laboratory HCV RNA testing data. HCV testing activity between... Read More about Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection.

Use of short-tandem repeat (STR) fingerprinting to validate sample origins in hepatitis C virus molecular epidemiology studies (2014)
Journal Article
Edwards, V. C., McClure, P., Brown, R. J., Thompson, E., Irving, W. L., & Ball, J. K. (in press). Use of short-tandem repeat (STR) fingerprinting to validate sample origins in hepatitis C virus molecular epidemiology studies. Journal of General Virology, 95(1), https://doi.org/10.1099/vir.0.057828-0

Sequence analysis is used to define the molecular epidemiology and evolution of the hepatitis C virus. Whilst most studies have shown that individual patients harbour viruses that are derived from a limited number of highly related strains, some rece... Read More about Use of short-tandem repeat (STR) fingerprinting to validate sample origins in hepatitis C virus molecular epidemiology studies.

The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy (2013)
Journal Article
Backx, M., Lewszuk, A., White, J., Cole, J., Sreedharan, A., van Sanden, S., …Irving, W. L. (2014). The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy. Journal of Viral Hepatitis, 21(3), https://doi.org/10.1111/jvh.12132

Chronic hepatitis C virus (HCV) infection places a considerable economic burden on health services. Cost-effectiveness analyses of antiviral treatment for patients with chronic HCV infection are dependent on assumptions about cost reductions followin... Read More about The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.

Act now against new NHS competition regulations (2013)
Journal Article
Davis, J., Banks, I., Wrigley, D., Peedell, C., Pollock, A., McPherson, K., …Chandy, R. (2013). Act now against new NHS competition regulations. BMJ, 346, https://doi.org/10.1136/bmj.f1819

An open letter to the BMA and the Academy of Medical Royal Colleges calls on them to make a joint public statement of opposition to the amended section 75 regulations

Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: Genetic subtype defines antigenic but not neutralization serotype (2011)
Journal Article
Tarr, A. W., Urbanowicz, R. A., Hamed, M. R., Albecka, A., McClure, C. P., Brown, R. J., …Ball, J. K. (2011). Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: Genetic subtype defines antigenic but not neutralization serotype. Journal of Virology, 85(9), 4246-4257. https://doi.org/10.1128/JVI.01332-10

Neutralizing antibodies have a role in controlling hepatitis C virus (HCV) infection. A successful vaccine will need to elicit potently neutralizing antibodies that are capable of preventing the infection of genetically diverse viral isolates. Howeve... Read More about Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: Genetic subtype defines antigenic but not neutralization serotype.

Increasing uptake of hepatitis C virus infection case- finding, testing, and treatment in primary care: evaluation of the HepCATT (Hepatitis C Assessment Through to Treatment) trial (2009)
Journal Article
Horwood, J., Clement, C., Roberts, K., Waldron, C., Irving, W., Macleod, J., & Hickman, M. (2009). Increasing uptake of hepatitis C virus infection case- finding, testing, and treatment in primary care: evaluation of the HepCATT (Hepatitis C Assessment Through to Treatment) trial. Journal of Clinical Virology, 44(2), https://doi.org/10.3399/bjgp20x708785

Background Hepatitis C virus (HCV) infection is a key cause of liver disease but can be cured in more than 95% of patients. Around 70 000 people in England may have undiagnosed HCV infection and many more will not have been treated. Interventions to... Read More about Increasing uptake of hepatitis C virus infection case- finding, testing, and treatment in primary care: evaluation of the HepCATT (Hepatitis C Assessment Through to Treatment) trial.

Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease (2008)
Journal Article
Hamed, M. R., Tarr, A. W., McClure, C. P., Ball, J. K., Hickling, T. P., & Irving, W. L. (2008). Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease. Journal of Viral Hepatitis, 15(5), 339-345. https://doi.org/10.1111/j.1365-2893.2007.00947.x

Hepatitis C virus (HCV) causes acute and chronic liver diseases in humans. Its two envelope glycoproteins, E1 and E2, provide a target for host immune recognition. HCV genotypes are classified into six genetic groups. To study the role of anti-HCV E1... Read More about Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease.

Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33 (2007)
Journal Article
Tarr, A. W., Owsianka, A. M., Jayaraj, D., Brown, R. J., Hickling, T. P., Irving, W. L., …Ball, J. K. (2007). Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. Journal of General Virology, 88(11), 2991-3001. https://doi.org/10.1099/vir.0.83065-0

Hepatitis C virus (HCV) is a major cause of liver disease worldwide and there is a pressing need for the development of a preventative vaccine as well as new treatments. It was recently demonstrated that the mouse monoclonal antibody (mAb) AP33 poten... Read More about Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.

Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes (2007)
Journal Article
Brown, R. J., Tarr, A. W., McClure, C. P., Juttla, V. S., Tagiuri, N., Irving, W. L., & Ball, J. K. (2007). Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes. Journal of General Virology, 88(2), 458-469. https://doi.org/10.1099/vir.0.82357-0

Investigation of the mechanisms underlying hepatitis C virus (HCV) envelope glycoprotein gene evolution will greatly assist rational development of broadly neutralizing antibody-based vaccines or vaccine components. Previously, comprehensive cross-ge... Read More about Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes.

General practice characteristics associated with rates of testing and detection of hepatitis C: Cross-sectional study in Nottingham and Derbyshire (2006)
Journal Article
Coupland, C., Hippisley-Cox, J., Smith, S., Irving, W., Pringle, M., Ryder, S., …Bullock, D. (2006). General practice characteristics associated with rates of testing and detection of hepatitis C: Cross-sectional study in Nottingham and Derbyshire. British Journal of General Practice, 56(529), 620-623

The aim of this study was to determine general practice characteristics associated with testing rates for hepatitis C virus (HCV) and the proportion of tests with a positive result. The study included all patients tested for HCV from all general prac... Read More about General practice characteristics associated with rates of testing and detection of hepatitis C: Cross-sectional study in Nottingham and Derbyshire.

Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection (2005)
Journal Article
Brown, R. J., Juttla, V. S., Tarr, A. W., Finnis, R., Irving, W. L., Hemsley, S., …Ball, J. K. (2005). Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection. Journal of General Virology, 86(7), 1931-1942. https://doi.org/10.1099/vir.0.80957-0

Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are important targets for the host immune response. The genes encoding these proteins exhibit a high degree of variability that gives rise to differing phenotypic traits, including alterations... Read More about Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection.